0726 GMT - AstraZeneca's shares are valued slightly ahead of its peers, but they remain well below their historical valuations, Shore Capital Markets says. The Anglo-Swedish pharmaceutical company's second-quarter results exceeded expectations, with guidance reiterated. AstraZeneca should be able to deliver on its longer-term growth ambitions, and fair value for the share price should be around 13,500 pence, Shore Capital's Sean Conroy says in a research note. This is a premium to the company's peers, justified given its pipeline momentum, limited exposure to patent expirations this decade and earnings potential, Conroy says. That said, uncertainty stoked by the U.S. political backdrop could continue to weigh on shares and fuel a degree of volatility until better visibility emerges, Conroy adds. Shore retains its buy recommendation. Shares are up 0.8% at 10,878 pence.(joseph.hoppe@wsj.com)
(END) Dow Jones Newswires
July 29, 2025 03:26 ET (07:26 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.